Liquid biopsy: the current state of the issue
Open Access
- 23 September 2021
- journal article
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 57-63
Abstract
Background Liquid biopsy is a promising method of diagnosing malignant tumors. It allows determining the level of free circulating tumor cells – micrometastases, tumor DNA, microRNA and exosomes in blood plasma, as well as detecting various genetic changes. This work included a literature review of current scientific publications on liquid biopsy techniques indexed in PubMed.Objective The aim of the study was to evaluate the efficacy and peculiarities of this technique in comparison with standard methods of morphological verification of oncological diseases, as well as the feasibility of its use in clinical practice. Compared to tissue biopsy LB has the following advantages: simplicity and speed of examination, easy repeatability and low invasiveness, possibility of dynamic monitoring of tumor progression – general clonal transformation as well as the appearance of resistance to treatment. The disadvantages of this method include low sensitivity, difficulty in proper interpretation of biomarkers and determination of their specificity, high risk of false positive and false negative results due to the presence of dormant tumor cells.Conclusion Currently, liquid biopsy analysis in clinical practice requires standardization and continuous validation.Keywords
This publication has 40 references indexed in Scilit:
- Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancerNature Medicine, 2014
- Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNACancer Discovery, 2014
- The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer PatientsInternational Journal of Molecular Sciences, 2013
- Cancer Genome LandscapesScience, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung AdenocarcinomasClinical Cancer Research, 2011
- Circulating cell-free DNA in plasma of melanoma patients: Qualitative and quantitative considerationsClinica Chimica Acta, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Prélèvements anatomopathologiques en cancérologie : règles de bonnes pratiques au bloc opératoireAnnales de Chirurgie, 2003